Copy to clipboard 
Cartilage repair is a rapidly expanding field within orthopedics, driven by the substantial unmet clinical need to address articular cartilage defects and degenerative joint disease. Cartilage injuries are highly prevalent, affecting millions of individuals worldwide through trauma, sports-related injury, and age-related degenerative processes.
The market encompasses a diverse array of treatment modalities, ranging from minimally invasive surgical techniques to advanced biologics and tissue-engineered solutions. As treatment paradigms continue to evolve toward preserving joint structure and function, the introduction of next-generation technologies promises to reshape clinical practice and greatly expand treatment options.
Recently, we had the opportunity to meet with many of the leading firms at the 18th International Cartilage Regeneration & Joint Preservation Society Meeting in Boston.
Current Treatment Modalities
Cartilage repair strategies are traditionally categorized by treatment approach: microfracture, osteochondral transplantation, cell-based therapies and biomaterial scaffold solutions. The diversity of available treatments reflects the reality that cartilage defects are not managed with a single standardized approach.
Microfracture or marrow-stimulation techniques involve arthroscopic perforation of subchondral bone to promote healing through mobilization of bone marrow-derived mesenchymal stem cells. While offering accessibility and relative simplicity, this technique is primarily indicated for focal defects of limited size and typically results in fibrocartilage rather than hyaline cartilage restoration. Enhanced microfracture variants, such as autologous matrix-induced chondrogenesis (AMIC), combine traditional microfracture with application of biological matrices or scaffolds to optimize repair outcomes and extend applicability to larger defects.
Osteochondral transplantation addresses full-thickness chondral and osteochondral defects through either autologous sources (autologous osteochondral autograft transfer, or OATS) or allogeneic sources (fresh or preserved allograft tissue). Autologous procedures offer biological compatibility but are limited by donor site morbidity and the finite volume of harvestable tissue. Allograft approaches overcome these constraints, providing ready-to-use solutions with immediate off-the-shelf availability. Fresh allograft tissues demonstrate superior integration and longer-term durability compared to preserved variants, though storage logistics and immunogenic considerations necessitate careful patient selection and tissue matching.
Vericel’s MACI has evolved into the standard treatment for managing severe focal cartilage defects. MACI utilizes autologous cultured chondrocytes seeded onto a porcine collagen membrane to support cartilage restoration. MACI reached market through FDA’s rigorous Biologics License Application (BLA) pathway and remains the only approved cell therapy for orthopedics. Despite this notable regulatory approval, the high cost of treatment —over $50,000 per graft —limits access to patients with severe cartilage defects.
Smith+Nephew’s Agili-C received FDA approval in 2022 and remains in the early stages of product launch. Agili-C is a biphasic scaffold derived from coral exoskeleton and is designed for single-stage osteochondral defect repair. The biphasic structure features a bone-facing layer that supports subchondral bone restoration and a cartilage-facing layer with micro-drilled channels to facilitate cell migration. The scaffold is gradually absorbed as native cartilage is restored. Agil-C presents a markedly different surgical and economic value proposition relative to MACI; however, it remains to be seen to what extent this technology will be accepted into clinical practice.
Product Development Landscape
Building upon the above advancements in cartilage repair, there are over 30 companies seeking to develop next-generation cartilage-repair products that are more effective, reliable, easier to use and cost-effective compared to current solutions.
The four programs highlighted below are the most developmentally mature, with each having the potential to obtain FDA approval by 2030.
Anika Therapeutics (HYALOFAST)
HYALOFAST is novel biomaterial scaffold derived from esterified hyaluronic acid, also known as HYAFF-11. The product is a resorbable, regenerative scaffold intended to be combined with bone marrow aspirate concentrate (BMAC) to support restoration of focal cartilage defects. HYALOFAST received CE Mark approval in 2013 and is commercially available in over 35 countries around the world.
In the U.S., HYALOFAST is regulated as a “device-biologic combination product” through CBER and requires premarket approval (PMA) to reach market. To support the PMA, Anika sponsored a 200-patient pivotal study to compare the performance of HYALOFAST to microfracture. Disappointingly, the pivotal study failed to meet the co-primary endpoints at the two-year post-operative endpoint (i.e. superiority in KOOS pain and IKDC function). Despite this setback, Anika believes the totality of data supporting HYALOFAST is sufficiently compelling to support a PMA filing, including achievement of key secondary endpoints and real-world evidence supporting safety and effectiveness. Accordingly, Anika submitted the final module of the PMA in November 2025 and will learn more about HYALOFAST’s approvability later in 2026.
Octane Medical (NOVOCART 3D)
NOVOCART 3D is a cell therapy product derived from cultured autologous chondrocytes seeded onto a bi-layered collagen scaffold. The product was originally developed by German-based TETEC AG and Aesculap and now is owned by Canadian-based Octane Medical Group. The product is intended to compete directly with Vericel’s MACI at the premium end of the cartilage implant market.
Enrollment in NOVACART 3D’s 233-patient pivotal trial was completed at the end of 2023, and top-line data from the study are expected in late 2025 or early 2026. As with many other cartilage repair products, NOVOCART 3D has a long clinical history in international markets, with over 24,000 treated patients since launching in 2003.
Geistlich Pharma (Chondro-Gide)
Chondro-Gide is a bilayer collagen membrane comprised of Type I and III porcine collagen. The product has been used widely in Europe for over 25 years in AMIC procedures. In this technique, Chondro-Gide is used as a “cover” following a microfracture or bone marrow stimulation procedure to retain liberated cells, factors and marrow elements within the cartilage defect area.
In the United States, Geistlich is pursuing the De Novo pathway through FDA. The company sponsored a 234-patient clinical trial to support the De Novo filing, which completed enrollment at the end of 2024. Top-line results are expected at end of 2026. The study design was noteworthy: patient outcomes from large lesions treated with Chondro-Gide and microfracture were compared to treatment of small lesions with microfracture alone.
Regentis Biomaterials (Gelrin-C)
Gelrin-C is an injectable and degradable elastomeric hydrogel that cures upon the application of ultraviolet light. The solidified gel conforms to topography of the defect and is intended to prevent the formation of fibrous tissue that typically occurs following a standard microfracture procedure. Over time the gel resorbs, exposing newly formed regenerated tissue underneath.
Regentis is an early-stage company and has struggled to obtain funding following the COVID-19 pandemic. The pivotal clinical trial needed to support a future PMA submission is on hold, after enrolling 47 patients. Most recently, Regentis filed to go public on NASDAQ, with the proceeds intended to support reactivation of patient enrollment and operational activities leading to a PMA submission.
Spotlight on Early-Stage Companies
Next, we highlight these early-stage companies that are of particular interest in cartilage repair due to their novelty and sustained progress toward human translation.
NanoChon is developing ChondroGraft, a 3D-printed nanoporous nylon implant for single-stage defect repair. After demonstrating impressive results in an equine model, NanoChon expects to begin enrolling patients in a First-in-Human clinical study in Canada by year end.
Askel Healthcare is developing COPLA, a fully synthetic implant intended to support immediate post-operative weight-bearing and improved recovery time. Upon completing a 20-patient clinical trial, Askel now intends to advance into a pivotal study.
Hy2Care is developing CartRevive, an injectable hydrogel that enables complete defect filling and new tissue formation. Hy2Care expects to begin enrolling patients in a U.S. IDE trial in 2026.
Cartilage Repair Hyped on Social Media
This review would be remiss if we failed to mention the curious case of ChondroFiller, whose story grabbed considerable attention on social media earlier this year. ChondroFiller is an injectable, self-setting formulation of collagen and is commercially available in select countries in Europe, Asia and Central America.
A Facebook post from August 2025 described ChondroFiller as “an injectable gel that regrows cartilage” that quickly went viral. The posts further claimed these benefits were possible with “no rehab, no medication, no risk of rejection”. Enthusiasm for the product went unchecked for several weeks, before multiple sources discredited the veracity of the claims.
This episode highlights the challenges of accurately communicating complex medical information to lay audiences, and the potential of social media to distort reality. As always, don’t believe everything you read! To be clear, we are unaware of any active product development or clinical activity regarding ChondroFiller that would support FDA approval in cartilage repair over the near term.
In Summary
The cartilage repair market reflects a field in transition from palliative surgical approaches toward regenerative and reparative paradigms. Enthusiasm for the robust pipeline of new products is warranted; however, it must be tempered by the historical difficulty in demonstrating clinical benefit in cartilage repair. Moreover, the pathway to obtaining FDA approval is difficult and lengthy, as the basis for approval requires considerably more than a tantalizing press release or fervent social media post.
We remain dedicated to supporting industry leaders and innovators in cartilage repair and look forward to sharing future advancements in clinical care as they become available.
James Petricek, MSE, MBA, is Vice President at the Bruder Consulting & Venture Group (BCVG), where he leads engagements in product and business strategy, market assessment, financial modeling, and due diligence. Additionally, he leads BCVG’s orthobiologic market research activities, tracking emerging trends and innovations in bone, tendon, ligament, cartilage, and intervertebral disc regeneration.
Scott Bruder, MD, PhD, FORS is the Founder and CEO of BCVG, which began providing expert guidance and tactical support in 2015. Together with their colleagues, the team has completed over 800 projects for more than 150 Client Partners in the field of Regenerative Medicine.
Cartilage repair is a rapidly expanding field within orthopedics, driven by the substantial unmet clinical need to address articular cartilage defects and degenerative joint disease. Cartilage injuries are highly prevalent, affecting millions of individuals worldwide through trauma, sports-related injury, and age-related degenerative...
Cartilage repair is a rapidly expanding field within orthopedics, driven by the substantial unmet clinical need to address articular cartilage defects and degenerative joint disease. Cartilage injuries are highly prevalent, affecting millions of individuals worldwide through trauma, sports-related injury, and age-related degenerative processes.
The market encompasses a diverse array of treatment modalities, ranging from minimally invasive surgical techniques to advanced biologics and tissue-engineered solutions. As treatment paradigms continue to evolve toward preserving joint structure and function, the introduction of next-generation technologies promises to reshape clinical practice and greatly expand treatment options.
Recently, we had the opportunity to meet with many of the leading firms at the 18th International Cartilage Regeneration & Joint Preservation Society Meeting in Boston.
Current Treatment Modalities
Cartilage repair strategies are traditionally categorized by treatment approach: microfracture, osteochondral transplantation, cell-based therapies and biomaterial scaffold solutions. The diversity of available treatments reflects the reality that cartilage defects are not managed with a single standardized approach.
Microfracture or marrow-stimulation techniques involve arthroscopic perforation of subchondral bone to promote healing through mobilization of bone marrow-derived mesenchymal stem cells. While offering accessibility and relative simplicity, this technique is primarily indicated for focal defects of limited size and typically results in fibrocartilage rather than hyaline cartilage restoration. Enhanced microfracture variants, such as autologous matrix-induced chondrogenesis (AMIC), combine traditional microfracture with application of biological matrices or scaffolds to optimize repair outcomes and extend applicability to larger defects.
Osteochondral transplantation addresses full-thickness chondral and osteochondral defects through either autologous sources (autologous osteochondral autograft transfer, or OATS) or allogeneic sources (fresh or preserved allograft tissue). Autologous procedures offer biological compatibility but are limited by donor site morbidity and the finite volume of harvestable tissue. Allograft approaches overcome these constraints, providing ready-to-use solutions with immediate off-the-shelf availability. Fresh allograft tissues demonstrate superior integration and longer-term durability compared to preserved variants, though storage logistics and immunogenic considerations necessitate careful patient selection and tissue matching.
Vericel’s MACI has evolved into the standard treatment for managing severe focal cartilage defects. MACI utilizes autologous cultured chondrocytes seeded onto a porcine collagen membrane to support cartilage restoration. MACI reached market through FDA’s rigorous Biologics License Application (BLA) pathway and remains the only approved cell therapy for orthopedics. Despite this notable regulatory approval, the high cost of treatment —over $50,000 per graft —limits access to patients with severe cartilage defects.
Smith+Nephew’s Agili-C received FDA approval in 2022 and remains in the early stages of product launch. Agili-C is a biphasic scaffold derived from coral exoskeleton and is designed for single-stage osteochondral defect repair. The biphasic structure features a bone-facing layer that supports subchondral bone restoration and a cartilage-facing layer with micro-drilled channels to facilitate cell migration. The scaffold is gradually absorbed as native cartilage is restored. Agil-C presents a markedly different surgical and economic value proposition relative to MACI; however, it remains to be seen to what extent this technology will be accepted into clinical practice.
Product Development Landscape
Building upon the above advancements in cartilage repair, there are over 30 companies seeking to develop next-generation cartilage-repair products that are more effective, reliable, easier to use and cost-effective compared to current solutions.
The four programs highlighted below are the most developmentally mature, with each having the potential to obtain FDA approval by 2030.
Anika Therapeutics (HYALOFAST)
HYALOFAST is novel biomaterial scaffold derived from esterified hyaluronic acid, also known as HYAFF-11. The product is a resorbable, regenerative scaffold intended to be combined with bone marrow aspirate concentrate (BMAC) to support restoration of focal cartilage defects. HYALOFAST received CE Mark approval in 2013 and is commercially available in over 35 countries around the world.
In the U.S., HYALOFAST is regulated as a “device-biologic combination product” through CBER and requires premarket approval (PMA) to reach market. To support the PMA, Anika sponsored a 200-patient pivotal study to compare the performance of HYALOFAST to microfracture. Disappointingly, the pivotal study failed to meet the co-primary endpoints at the two-year post-operative endpoint (i.e. superiority in KOOS pain and IKDC function). Despite this setback, Anika believes the totality of data supporting HYALOFAST is sufficiently compelling to support a PMA filing, including achievement of key secondary endpoints and real-world evidence supporting safety and effectiveness. Accordingly, Anika submitted the final module of the PMA in November 2025 and will learn more about HYALOFAST’s approvability later in 2026.
Octane Medical (NOVOCART 3D)
NOVOCART 3D is a cell therapy product derived from cultured autologous chondrocytes seeded onto a bi-layered collagen scaffold. The product was originally developed by German-based TETEC AG and Aesculap and now is owned by Canadian-based Octane Medical Group. The product is intended to compete directly with Vericel’s MACI at the premium end of the cartilage implant market.
Enrollment in NOVACART 3D’s 233-patient pivotal trial was completed at the end of 2023, and top-line data from the study are expected in late 2025 or early 2026. As with many other cartilage repair products, NOVOCART 3D has a long clinical history in international markets, with over 24,000 treated patients since launching in 2003.
Geistlich Pharma (Chondro-Gide)
Chondro-Gide is a bilayer collagen membrane comprised of Type I and III porcine collagen. The product has been used widely in Europe for over 25 years in AMIC procedures. In this technique, Chondro-Gide is used as a “cover” following a microfracture or bone marrow stimulation procedure to retain liberated cells, factors and marrow elements within the cartilage defect area.
In the United States, Geistlich is pursuing the De Novo pathway through FDA. The company sponsored a 234-patient clinical trial to support the De Novo filing, which completed enrollment at the end of 2024. Top-line results are expected at end of 2026. The study design was noteworthy: patient outcomes from large lesions treated with Chondro-Gide and microfracture were compared to treatment of small lesions with microfracture alone.
Regentis Biomaterials (Gelrin-C)
Gelrin-C is an injectable and degradable elastomeric hydrogel that cures upon the application of ultraviolet light. The solidified gel conforms to topography of the defect and is intended to prevent the formation of fibrous tissue that typically occurs following a standard microfracture procedure. Over time the gel resorbs, exposing newly formed regenerated tissue underneath.
Regentis is an early-stage company and has struggled to obtain funding following the COVID-19 pandemic. The pivotal clinical trial needed to support a future PMA submission is on hold, after enrolling 47 patients. Most recently, Regentis filed to go public on NASDAQ, with the proceeds intended to support reactivation of patient enrollment and operational activities leading to a PMA submission.
Spotlight on Early-Stage Companies
Next, we highlight these early-stage companies that are of particular interest in cartilage repair due to their novelty and sustained progress toward human translation.
NanoChon is developing ChondroGraft, a 3D-printed nanoporous nylon implant for single-stage defect repair. After demonstrating impressive results in an equine model, NanoChon expects to begin enrolling patients in a First-in-Human clinical study in Canada by year end.
Askel Healthcare is developing COPLA, a fully synthetic implant intended to support immediate post-operative weight-bearing and improved recovery time. Upon completing a 20-patient clinical trial, Askel now intends to advance into a pivotal study.
Hy2Care is developing CartRevive, an injectable hydrogel that enables complete defect filling and new tissue formation. Hy2Care expects to begin enrolling patients in a U.S. IDE trial in 2026.
Cartilage Repair Hyped on Social Media
This review would be remiss if we failed to mention the curious case of ChondroFiller, whose story grabbed considerable attention on social media earlier this year. ChondroFiller is an injectable, self-setting formulation of collagen and is commercially available in select countries in Europe, Asia and Central America.
A Facebook post from August 2025 described ChondroFiller as “an injectable gel that regrows cartilage” that quickly went viral. The posts further claimed these benefits were possible with “no rehab, no medication, no risk of rejection”. Enthusiasm for the product went unchecked for several weeks, before multiple sources discredited the veracity of the claims.
This episode highlights the challenges of accurately communicating complex medical information to lay audiences, and the potential of social media to distort reality. As always, don’t believe everything you read! To be clear, we are unaware of any active product development or clinical activity regarding ChondroFiller that would support FDA approval in cartilage repair over the near term.
In Summary
The cartilage repair market reflects a field in transition from palliative surgical approaches toward regenerative and reparative paradigms. Enthusiasm for the robust pipeline of new products is warranted; however, it must be tempered by the historical difficulty in demonstrating clinical benefit in cartilage repair. Moreover, the pathway to obtaining FDA approval is difficult and lengthy, as the basis for approval requires considerably more than a tantalizing press release or fervent social media post.
We remain dedicated to supporting industry leaders and innovators in cartilage repair and look forward to sharing future advancements in clinical care as they become available.
James Petricek, MSE, MBA, is Vice President at the Bruder Consulting & Venture Group (BCVG), where he leads engagements in product and business strategy, market assessment, financial modeling, and due diligence. Additionally, he leads BCVG’s orthobiologic market research activities, tracking emerging trends and innovations in bone, tendon, ligament, cartilage, and intervertebral disc regeneration.
Scott Bruder, MD, PhD, FORS is the Founder and CEO of BCVG, which began providing expert guidance and tactical support in 2015. Together with their colleagues, the team has completed over 800 projects for more than 150 Client Partners in the field of Regenerative Medicine.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
